Health Care

Biogen’s new Alzheimer’s drug could cost Medicaid up to $2.2 billion a year

A pricey new Alzheimer’s drug already mired in controversy could cost Medicaid anywhere from $720 million to nearly $2.2 billion each year depending on the number of patients treated, according to a new analysis.

The medication, which is called Aduhelm and carries a $56,000 price tag, is generating concern over its potential impact on the overall health care system. The Centers for Medicare & Medicaid Services, for instance, is about to begin a process for determining whether Medicare will establish a national coverage policy for the drug, which is sold by Biogen (BIIB) and won regulatory approval last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED



 Source link

Back to top button